Skip to main content
Premium Trial:

Request an Annual Quote

Human Longevity Completes $220M Series B Financing

NEW YORK (GenomeWeb) – Human Longevity announced on Monday that it has completed a $220 million offering of Series B preferred stock.

The firm plans to use the proceeds to grow its business and expand its product offerings, including Health Nucleus, a comprehensive, genomic-enhanced, research-based health center; ongoing development of the HLI Knowledgebase which currently has more than 20,000 complete genomes coupled with phenotype data; the Comprehensive Cancer Program; and other sequencing programs.

Investors in this financing round include Illumina, Celgene, GE Ventures, and participants in the $80 million Series A round the firm closed in 2014.

"The closing of our Series B offering was completed with excellent results for HLI, despite especially challenging external financial markets," said Co-founder and CEO J. Craig Venter in a statement. "This is a tribute to the strength of our science, technology, and team. We continue to build our business, develop life-changing products, and hire world-class scientific, clinical, and technical leaders to help us meet our goal of revolutionizing healthcare."

The Scan

Monkeypox Meeting

As the World Health Organization gets ready to hold another monkeypox meeting, the US distributes vaccines and increases its testing capacity.

CRISPR's Softer Side

A homologous chromosome-templated repair approach to gene editing relies on versions of the Cas9 enzyme that cut a single DNA strand.

Pickled? No Problem

Researchers come up with an approach for extracting DNA from archived museum specimens. 

Nature Papers on Long Reads for Bacterial Genomes, Zebrafish Atlas, Hypothalamic Aging in Mammals

In Nature this week: near-finished microbial genomes without polishing, zebrafish functional annotation program, and more.